Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man.
D007516:Adenoma, Islet Cell / Q000097:blood*; D001120:Arginine / Q000037:antagonists & inhibitors; D001786:Blood Glucose / Q000032:analysis; D002395:Catecholamines / Q000032:analysis; D003864:Depression, Chemical; D003981:Diazoxide / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005934:Glucagon / Q000037:antagonists & inhibitors; D005947:Glucose / Q000037:antagonists & inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D006946:Hyperinsulinism / Q000097:blood*; D007003:Hypoglycemia / Q000188:drug therapy; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D007930:Leucine / Q000037:antagonists & inhibitors; D008297:Male; D014044:Tolbutamide / Q000037:antagonists & inhibitors; D014237:Trichlormethiazide / Q000494:pharmacology
D001786:Blood Glucose; D002395:Catecholamines; D007328:Insulin; D005934:Glucagon; D001120:Arginine; D014044:Tolbutamide; D007930:Leucine; D005947:Glucose; D003981:Diazoxide; D014237:Trichlormethiazide